(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.

Details are as follows:

Event: Guggenheim 2^nd Annual Healthcare Innovation Conference
Date: November 11, 2025
Time: 8:00 AM ET
Format: Fireside Chat

Event: Jefferies London Healthcare Conference
Date: November 17, 2025
Time: 4:30 PM GMT
Format: Presentation

The live webcast for the events can be accessed in the Investors section on the Company's website at . Replays of the presentations will be available for at least 30 days.

Cidara will also participate in one-on-one investor meetings during the conferences.

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak^® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
...

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
...

MENAFN28102025004107003653ID1110258663